Abstract
Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients. © 2011 Elsevier Ltd.
| Original language | English |
|---|---|
| Pages (from-to) | 2836-2839 |
| Number of pages | 4 |
| Journal | Vaccine |
| Volume | 29 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- General Immunology and Microbiology
- General Veterinary
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Keywords
- Adjuvants
- Adult
- Antibodies
- CD4 Lymphocyte Count
- Environmental and Occupational Health
- Female
- H1N1 Subtype
- HIV
- HIV Infections
- Hemagglutinin Glycoproteins
- Human
- Humans
- Immunogenicity
- Immunologic
- Immunology and Microbiology (all)
- Infectious Diseases
- Influenza
- Influenza A (H1N1)
- Influenza A Virus
- Influenza Vaccines
- Influenza Virus
- Male
- Middle Aged
- Molecular Medicine
- Polysorbates
- Public Health
- Squalene
- Swine flu
- Vaccination
- Veterinary (all)
- Viral
Fingerprint
Dive into the research topics of 'Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver